Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 2, 2000, Pages 463-473

  Ekins, S ^a   Obach, R S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOBARBITAL; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; HEXOBARBITAL; IBUPROFEN; IMIPRAMINE; KETAMINE; LORCAINIDE; METHOHEXITAL; METHOXSALEN; MIDAZOLAM; PHENAZONE; PREDNISONE; PROPAFENONE; QUINIDINE; TENIDAP; TENOXICAM; TOLBUTAMIDE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZOLPIDEM;

ARTICLE; CATALYST; CHEMICAL STRUCTURE; COMPUTER PROGRAM; DRUG CLEARANCE; DRUG METABOLISM; LIVER CELL; MICROSOME; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CATALYSIS; HEPATOCYTES; HUMAN; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 0033776103     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man
2. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes
3. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
4. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
5. Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism
6. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
7. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
8. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
9. Three dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates
10. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes
11. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium
12. Drug metabolism/drug interaction studies in the drug development process: Studies in vitro
13. In vivo drug metabolism/drug interaction studies: Study design, data analysis, and recommendations for dosing and labeling
14. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers
15. Predicting the hepatic clearance of xenobiotics in humans from in vitro data
16. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
17. Prediction of In vivo drug metabolism in the human liver from in vitro metabolism data
18. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
19. Predictability of the in vivo metabolism of verapamil from in vitro data; contribution of individual metabolic pathways and stereoselective aspects
20. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans
21. The prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of the in vitro half life approach and non-specific binding to microsomes
22. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
23. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in man
24. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques
25. Alterations in the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices
26. The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance
27. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds
28. Kinetics of drug metabolism in rat liver slices: Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds
29. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
30. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development